Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | PLK1 | P53350 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.57 |
| ▸ | RARB | P10826 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RARA | P10276 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22438945 | 1.00 | THRA (0.62) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL7829330 | 1.00 | THRA (0.62) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL28477008 | 1.00 | THRA (0.62) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL9365114 | 1.00 | THRA (0.62) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL12080799 | 1.00 | THRA (0.62) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL11573788 | 0.98 | THRA (0.60) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL10528100 | 0.95 | RARB (0.61) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL10528096 | 0.95 | RARB (0.61) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL10529851 | 0.95 | RARB (0.61) | THRATHRBPLK1TP53TSHR | |
| SCHEMBL10536522 | 0.95 | RARB (0.61) | THRATHRBPLK1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815478-B2 | Colored curable composition, resist liquid, ink for inkjet printing, color filter, method of producing color filter, solid-state image sensor, liquid crystal display, organic EL display, image display device and colorant compound | FUJIFILM CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20120264039-A1 | COLORED CURABLE COMPOSITION, RESIST LIQUID, INK FOR INKJET PRINTING, COLOR FILTER, METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR, LIQUID CRYSTAL DISPLAY, ORGANIC EL DISPLAY, IMAGE DISPLAY DEVICE AND COLORANT COMPOUND | FUJIFILM CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| US-4014932-A | ANTHELMINTICS, PESTICIDES, MITICIDES, INSECTICIDES | THE UPJOHN COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-3980685-A | Magnesium-aluminum containing complexes of organic anions of central nervous system affecting compounds | KYOWA CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-09-14 | — | — | US | disclosed |
| US-3931318-A | ANTHELMINTICS, PESTICIDES | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264039-A1 | COLORED CURABLE COMPOSITION, RESIST LIQUID, INK FOR INKJET PRINTING, COLOR FILTER, METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR, LIQUID CRYSTAL DISPLAY, ORGANIC EL DISPLAY, IMAGE DISPLAY DEVICE AND COLORANT COMPOUND | CDYL, RET, NLRP1 | THRA 3268/4885THRB 3859/4885PLK1 2393/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | THRA 4083/4885THRB 2778/4885PLK1 3643/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | THRA 4083/4885THRB 2778/4885PLK1 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.